What is Neuroectodermal melanolysosomal disease?
Neuroectodermal melanolysosomal disease, also known as Elejalde syndrome or Griscelli syndrome type 1, is a very rare inherited condition that affects multiple body systems at once. The name comes from the fact that it involves both the nervous system (neuro) and the pigment-producing cells of the skin and hair (melanolysosomal). These pigment cells, called melanocytes, have tiny compartments inside them called lysosomes that store and move color pigment. In this disease, those compartments do not work properly, leading to unusual silvery or light-colored hair and skin from birth or early infancy. Beyond the changes in color, the most serious part of this disease is how it affects the brain and nervous system. Children with this condition often develop severe neurological problems, including seizures, muscle stiffness or weakness, intellectual disability, and loss of developmental milestones. Unlike some related conditions, the immune system may also be involved in some cases, though the neurological features tend to dominate. There is currently no cure for neuroectodermal melanolysosomal disease. Treatment focuses on managing symptoms, especially seizures and movement problems. Bone marrow transplantation has been explored in related conditions but its role here remains uncertain. The disease is typically severe, and families benefit greatly from a team of specialists working together to support the child and caregivers.
Also known as:
Key symptoms:
Silvery or light-colored hair from birthLighter than expected skin pigmentationSeizuresMuscle stiffness or spasticityMuscle weaknessIntellectual disabilityLoss of previously learned skills (developmental regression)Difficulty walking or coordinating movementsAbnormal eye movementsDelayed development of speech and motor skillsEnlarged liver or spleen in some cases
Clinical phenotype terms (29)— hover any for plain English
- Inheritance
- Autosomal recessive
- Passed on when both parents carry the same gene change; often skips generations
- Age of Onset
- Infantile
- Begins in infancy, roughly 1 month to 2 years old
Treatments
Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly
No FDA-approved treatments are currently listed for Neuroectodermal melanolysosomal disease.
View clinical trials →Clinical Trials
View all trials with filters →Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest
No actively recruiting trials found for Neuroectodermal melanolysosomal disease at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)
No specialists are currently listed for Neuroectodermal melanolysosomal disease.
Treatment Centers
8 centersSource: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months
Children's Hospital Colorado Rare Disease Program ↗
Children's Hospital Colorado
📍 Aurora, CO
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDBoston Children's Hospital Rare Disease Program ↗
Boston Children's Hospital
📍 Boston, MA
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
🏨 Children'sAnn & Robert H. Lurie Children's Hospital Genetics ↗
Lurie Children's Hospital
📍 Chicago, IL
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDCincinnati Children's Hospital Medical Center ↗
Cincinnati Children's
📍 Cincinnati, OH
👤 Boston Children's Hospital Rare Disease Program
🏨 Children'sNationwide Children's Hospital Rare Disease Center ↗
Nationwide Children's Hospital
📍 Columbus, OH
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
Travel Grants
No travel grants are currently matched to Neuroectodermal melanolysosomal disease.
Community
No community posts yet. Be the first to share your experience with Neuroectodermal melanolysosomal disease.
Start the conversation →Latest news about Neuroectodermal melanolysosomal disease
Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC
No recent news articles for Neuroectodermal melanolysosomal disease.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Which specific gene mutation does my child have, and what does that mean for their prognosis?,What anti-seizure medications are most appropriate, and what is the plan if seizures are not controlled?,Should we consider bone marrow transplantation, and would it help with the neurological symptoms?,What therapies — physical, occupational, or speech — should we start right away?,Are there any clinical trials or research studies we could participate in?,What signs should prompt us to go to the emergency room immediately?,Are other family members at risk, and should siblings or parents be tested?
Common questions about Neuroectodermal melanolysosomal disease
What is Neuroectodermal melanolysosomal disease?
Neuroectodermal melanolysosomal disease, also known as Elejalde syndrome or Griscelli syndrome type 1, is a very rare inherited condition that affects multiple body systems at once. The name comes from the fact that it involves both the nervous system (neuro) and the pigment-producing cells of the skin and hair (melanolysosomal). These pigment cells, called melanocytes, have tiny compartments inside them called lysosomes that store and move color pigment. In this disease, those compartments do not work properly, leading to unusual silvery or light-colored hair and skin from birth or early infa
How is Neuroectodermal melanolysosomal disease inherited?
Neuroectodermal melanolysosomal disease follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Neuroectodermal melanolysosomal disease typically begin?
Typical onset of Neuroectodermal melanolysosomal disease is infantile. Age of onset can vary across affected individuals.
Frequently asked questions about Neuroectodermal melanolysosomal disease
Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.
What is Neuroectodermal melanolysosomal disease?
Neuroectodermal melanolysosomal disease is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:33445, OMIM 256710). It is typically inherited as autosomal recessive. Age of onset is generally infantile. For verified primary sources, see the UniteRare Neuroectodermal melanolysosomal disease page.
How is Neuroectodermal melanolysosomal disease inherited?
Neuroectodermal melanolysosomal disease follows autosomal recessive inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.
Are there FDA-approved treatments for Neuroectodermal melanolysosomal disease?
Approved treatments for Neuroectodermal melanolysosomal disease are tracked from openFDA and DailyMed primary sources. Many rare diseases have no specific FDA-approved therapy; for those, supportive care and management of complications form the basis of clinical care. Orphan-drug-designation status is noted where applicable.
Are there clinical trials for Neuroectodermal melanolysosomal disease?
Active clinical trials for Neuroectodermal melanolysosomal disease are tracked daily from ClinicalTrials.gov. Trial availability changes frequently; check the UniteRare trial listings for the current count and recruitment status. Sponsors of rare-disease research often welcome inquiries even when a trial is not actively recruiting at a given moment.
How do I find a specialist for Neuroectodermal melanolysosomal disease?
Verified Neuroectodermal melanolysosomal disease specialists are identified through ClinicalTrials.gov principal-investigator records, peer-reviewed publication authorship (via PubMed), and the NPPES NPI registry. NORD-designated Centers of Excellence and NIH-affiliated rare-disease clinics are also tracked. UniteRare's specialist directory is updated continuously as new evidence becomes available.
See full Neuroectodermal melanolysosomal disease page for complete clinical details, sources, and verified-specialist listings.
Cite this page
Select a citation format above to view and copy.